These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 17233186)
41. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Corsini A; Ceska R Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551 [TBL] [Abstract][Full Text] [Related]
42. Statins differ significantly in their anti-inflammatory activity. Kwatra SG J Am Acad Dermatol; 2011 Dec; 65(6):1229; author reply 1229-30. PubMed ID: 22082842 [No Abstract] [Full Text] [Related]
43. [Residual risk of cardiovascular complications and its reduction with a combination of lipid lowering agents]. Soska V Vnitr Lek; 2011 Mar; 57(3):313-6. PubMed ID: 21495414 [TBL] [Abstract][Full Text] [Related]
44. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. Bottorff M; Hansten P Arch Intern Med; 2000 Aug 14-28; 160(15):2273-80. PubMed ID: 10927723 [No Abstract] [Full Text] [Related]
46. Drugs for hypertriglyceridemia. Med Lett Drugs Ther; 2013 Mar; 55(1411):17-9. PubMed ID: 23467119 [No Abstract] [Full Text] [Related]
47. Pitavastatin (Livalo)--the seventh statin. Med Lett Drugs Ther; 2010 Jul; 52(1343):57-8. PubMed ID: 20651638 [No Abstract] [Full Text] [Related]
48. Statins and cancer: a case of meta-uncertainty. Guallar E; Goodman SN Am J Med; 2001 Jun; 110(9):738-40. PubMed ID: 11403761 [No Abstract] [Full Text] [Related]
51. [Adverse drug reactions of hydroxymethylglutaryl-CoA reductase inhibitors reported to agency for medicinal products and medical devices]. Skvrce NM; Bozina N; Sarinić VM; Tomić S Lijec Vjesn; 2010; 132(9-10):277-82. PubMed ID: 21261024 [TBL] [Abstract][Full Text] [Related]
52. Never too old for lipid-lowering therapy. Boccara F Arch Cardiovasc Dis; 2021; 114(8-9):524-526. PubMed ID: 34257047 [No Abstract] [Full Text] [Related]
53. [Transplant coronary artery disease--treatment with statins]. Wolszakiewicz J; Bilińska M Pol Merkur Lekarski; 2004 May; 16(95):472-3. PubMed ID: 15518430 [TBL] [Abstract][Full Text] [Related]
54. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
55. Statin drug interactions and related adverse reactions. Bellosta S; Corsini A Expert Opin Drug Saf; 2012 Nov; 11(6):933-46. PubMed ID: 22866966 [TBL] [Abstract][Full Text] [Related]
56. An assessment of statin safety by muscle experts. Thompson PD; Clarkson PM; Rosenson RS; Am J Cardiol; 2006 Apr; 97(8A):69C-76C. PubMed ID: 16581332 [TBL] [Abstract][Full Text] [Related]
57. Studies on the interaction between fibrates and statins using human hepatic microsomes. Fujino H; Shimada S; Yamada I; Hirano M; Tsunenari Y; Kojima J Arzneimittelforschung; 2003; 53(10):701-7. PubMed ID: 14650362 [TBL] [Abstract][Full Text] [Related]
58. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Andreou ER; Ledger S Can J Clin Pharmacol; 2003; 10(4):172-4. PubMed ID: 14712320 [TBL] [Abstract][Full Text] [Related]
59. OTC statins: a bad decision for public health. Lancet; 2004 May; 363(9422):1659. PubMed ID: 15158622 [No Abstract] [Full Text] [Related]
60. Medication pitfalls in the CKD clinic: case presentations. Liles AM Adv Chronic Kidney Dis; 2014 Jul; 21(4):349-54. PubMed ID: 24969386 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]